NCT07486648 2026-03-24
Precision
Shanxi Province Cancer Hospital
Phase 1/2 Not yet recruiting
Clinical Trials
11 trialsNCT07485452 2026-03-20
OSIBBBOOST
Maastricht University Medical Center
Phase 2 Not yet recruiting
NCT07376382 2026-02-02
SYNSTAR-02
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 3 Not yet recruiting
NCT07361705 2026-01-23
Zorifertinib With Osimertinib for NSCLC With Meningeal Progression
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 1 Not yet recruiting
NCT07329322 2026-01-09
Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 2 Not yet recruiting
NCT07323641 2026-01-07
Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT07153055 2025-12-18
LOTS
Indiana University
Phase 1/2 Not yet recruiting
NCT07285148 2025-12-16
A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer
Beijing Pearl Biotechnology Limited Liability Company
Phase 1/2 Not yet recruiting
NCT07256509 2025-12-05
A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 2 Not yet recruiting
NCT07177092 2025-09-16
SURGAN-TKI
The First Affiliated Hospital of Guangzhou Medical University
Phase 2 Not yet recruiting
NCT07038460 2025-06-26
NEO-LISI
Guangdong Provincial People's Hospital
Phase 2 Not yet recruiting